A patient with an ST-segment elevation myocardial infarction is being discharged after successful PCI. What is the most appropriate recommendation for statin therapy?

Study for the Board Certified Cardiology Pharmacist Exam. Utilize flashcards and answer multiple-choice questions with detailed explanations. Prepare efficiently for your certification!

In the context of a patient discharged after a successful percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), the recommendation of atorvastatin 80 mg daily aligns with current clinical guidelines emphasizing the importance of high-intensity statin therapy in secondary prevention of cardiovascular events.

Atorvastatin at this dose has been shown to significantly reduce rates of cardiovascular morbidity and mortality in patients with a history of myocardial infarction. The high-intensity statin therapy is particularly beneficial due to its potent LDL-C lowering effects, which is crucial for patients with acute coronary syndrome and high cardiovascular risk. Guidelines recommend high-intensity statin therapy as standard care to improve outcomes after an event like an ST-segment elevation myocardial infarction.

Other statins or doses may not provide the same level of LDL-C reduction or cardiovascular protective effect as atorvastatin at the higher dosage. While rosuvastatin can also be considered a high-intensity statin, the specific dosing here does not represent a high-intensity strategy as effectively as atorvastatin 80 mg. Likewise, pravastatin and fluvastatin have lower potencies and would not be classified as high-intensity, thus falling short of current recommendations that favor more